Neuropsychiatrische Störungen bei Chorea Huntington

Detlef Wietelmann

doi:10.1055/a-1851-3700

PSYCH up2date, Table of Contents

PSYCH up2date 2022; 16(06): 473-489
DOI: 10.1055/a-1851-3700

Organische psychische Störungen

Neuropsychiatrische Störungen bei Chorea Huntington

Detlef Wietelmann

Abstract

All articles of this category

Die Chorea Huntington ist die häufigste neurodegenerative Erkrankung, die monogenetisch autosomal dominant vererbt wird und deren Diagnose anhand der CAG-Trinukleotidzahl meistens eindeutig präklinisch gestellt werden kann. Bislang ist der Verlauf trotz sehr spannender Therapieansätze, die eine Reduktion des Genprodukts anstreben, nicht aufzuhalten. Antidepressiva und hochpotente Neuroleptika sind die am häufigsten eingesetzten Medikamente.

Schlüsselwörter

Motorik - Neuropsychiatrie - Komorbidität - Suizidalität - Anosognosie - Psychopharmakotherapie

Full Text

References

Literatur
1 Frank W, Lindenberg KS, Mühlbäck A. et al. Krankheitsmodifizierende Therapieansätze bei der Huntington-Krankheit, Blicke zurück und Blicke voraus. Nervenarzt 2022; 93: 179-190
2 Dorsey ER, Beck CA, Darwin K. et al. Natural history of Huntington disease. JAMA Neurol 2013; 70: 1520-1530
3 Wexler A, Wild EJ, Tabrizi SJ. George Huntington: a legacy of inquiry, empathy and hope. Brain 2016; 139: 2326-2333
4 Cui S-S, Ren R-J, Wang Y. et al. Tics as an initial manifestation of juvenile Huntington’s disease: case report and literature review. BMC Neurology 2017; 17: 152
5 Zarotti N, Dale M, Eccles F. et al. Psychological interventions for people with Huntington’s disease: A call to arms. J Huntingtons Dis 2020; 9: 231-243
6 Rawlins MD, Wexler NS, Wexler AR. et al. The prevalence of Huntington’s disease. Neuroepidemiol 2016; 46: 144-153
7 Ohlmeier C, Saum K-U, Galetzka W. et al. Epidemiology and health care utilization of patients suffering from Huntington’s disease in Germany: real world evidence based on German claims data. BMC Neurology 2019; 19: 318
8 Solberg OK, Filkuková P, Frich JC. et al. Age at death and causes of death in patients with Huntington disease in Norway in 1986–2015. J Huntingtons Dis 2018; 7: 77-86
9 Saft C. et al. S2k-Leitlinie Chorea/Morbus Huntington. 2017. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. Accessed August 01, 2022 at: www.dgn.org/leitlinien
10 Fusilli C, Migliore S, Mazza T. et al. Biological and clinical manifestations of juvenile Huntington’s disease: a retrospective analysis. Lancet Neurol 2018; 17: 986-993
11 McAllister B, Gusella JF, Landwehrmeyer GB. et al. Timing and impact of psychiatric, cognitive, and motor abnormalities in Huntington disease. Neurol 2021; 96
12 Julayanont P, Heilmann KM, McFarland NR. et al. Early-motor phenotype relates to neuropsychiatric and cognitve disorders in Huntington’s disease. Mov Disord 2020; 35: 781-788
13 Bachoud-Lévi AC, Ferreira J, Massart R. et al. International Guidelines for the Treatment of Huntington’s disease. Front Neurol 2019; 10: 710
14 Teixeira AL, Cruz de Souza L, Pessoa Rocha N. et al. Revisiting the neuropsychiatry of Huntington’s disease. Dement Neuropsychol 2016; 10: 261-266
15 Coppen EM, Roos RAC. Current pharmacological approaches to reduce Chorea in Huntington’s disease. Drugs 2017; 77: 29-46
16 Orth M, Handley OJ, Schwenke C. et al. Observing Huntington’s Disease: the European Huntington’s Disease Network´s REGISTRY. PLOS Curr 2010; 2: RRN1184
17 Thompson JC, Harris J, Sollom AC. et al. Longitudinal evaluation of neuropsychiatric symptoms in Huntington’s disease. J Neuropsychiatry Clin Neurosci 2012; 24: 53-60
18 Nguyen HHP, Weydt P. Huntington Erkrankung. Medizinische genetik 2018; 30: 246-251
19 Julien CL, Thompson JC, Wild S. et al. Psychiatric disorders in preclinical Huntington’s disease. J Neurol Neurosurg Psychiatry 2007; 78: 939-943
20 Jensen P, Fenger K, Bolwig TG. et al. Crime in Huntington’s disease: a study of registered offences among patients, relatives, and controls. J Neurol Neurosurg Psychiatry 1998; 65: 467-471
21 Exuzides A, Matos JE, Patel AM. et al. Understanding the burden associated with Huntingtonʼs disease in manifest patients and care partners – Comparing to Parkinsonʼs Disease and the general population. Brain Sci 2022; 12: 161
22 European Huntington’s disease Network. Accessed September 01, 2022 at: www.ehdn.org
23 Tampi RR, Weber M, Masterson GA. et al. Early warnings: neuropsychiatric manifestations of Huntington’s disease. Psychiatric Times 2021; 38: 25-27
24 Adrissi J, Nadkarni NA, Gausche E. et al. Electroconvulsive therapy (ECT) for refractory psychiatric symptoms in Huntington’s disease: A case series and review of the literature. J Huntingtons Dis 2019; 8: 291-300
25 Mowafi W, Millard J. Electroconvulsive therapy for severe depression, psychosis and chorea in a patient with Huntington’s disease: case report and review of the literature. B J Psych Bull 2021; 45: 97-104
26 Anderson KE, van Duijn E, Craufurd D. et al. Clinical Management of neuropsychiatric symptoms of Huntington Disease: Expert-based consensus guidelines on agitation, anxiety, apathy, psychosis, and sleep disorders. J Huntingtons Dis 2018; 7: 355-366
27 Paulsen JS. Cognitive Impairment in Huntington’s Disease: Diagnosis and Treatment. Curr Neurol Neurosci Rep 2011; 11: 474-483
28 Zhang Y, Zhou J, Gehl CR. et al. Mild cognitive impairment as an early landmark in Huntington’s disease. Front Neurol 2021;
29 Peavy GM, Jacobson MW, Goldstein JL. et al. Cognitive and functional decline in Huntington’s disease: Dementia criteria revisited. Mov Disord 2010; 25: 1163-1169
30 Davis MY, Keene CD, Jayadev S. et al. The co-occurence of Alzheimer´s disease and Huntington’s disease: A neuropathological study of 15 elderly Huntington’s disease subjects. J Huntingtons Dis 2014; 3: 209-217
31 Julayanont P, McFarland NR, Heilmann KM. Mild cognitive impairment and dementia in motor manifest Huntington’s disease: Classification and prevalence. J Neurol Sci 2020; 408: 116523
32 Dorsey ER, Beck CA, Darwin K. et al. Natural history of Huntington’s disease. JAMA Neurol 2013; 70: 1520-1530
33 Stanley K, Whitfield T, Kuchenbaecker K. et al. Rate of cognitive decline in Alzheimer´s disease stratified by age. J Alzheimers Dis 2019; 69: 1153-1160
34 Vattakatuchery JJ, Kurien R. Acetylcholinesterase inhibitors in cognitve impairment in Huntington’s disease: A brief review. World J Psychiatr 2013; 22: 62-64
35 Li Y, Hai S, Zhou Y. et al. Cholinesterase inhibitors for rarer dementias associated with neurological conditions (review). Cochrane Database Syst Rev 2015; 3: CD009444
36 EppingEAPaulsen JS. Depression in early stages of Huntington’s disease. Neurodegener Dis Manag 2011; 1: 407-414
37 Julien CL, Thompson JC, Wild S. Psychiatric disorders in preclinical Huntington’s disease. Neurol Neurosurg Psychiatry 2007; 78: 939-943
38 Scheuing L, Chiu C-T, Liao H-M. et al. Preclinical and clinical investigations of mood stabilizers for Huntington’s disease: What have we learned?. Int J Biol Sci 2014; 10: 1024-1038
39 Greenberg M, Paddu N, Bhivandkar S. et al. Treating depression and suicidality in Huntington’s disease. Psychiatric Ann 2020; 50
40 Honrath P, Dogan I, Wudarczyk O. et al. Risk factors of suicidal ideation in Huntington’s disease: literature review and data from enroll-HD. J Neurol 2018; 265: 2548-2561
41 Van Duijn E, Fernandes AR, Abreu D. et al. Incidence of completed suicide and suicide attempts in a global prospective study of Huntington’s disease. BJ Psych Open 2021; 31: e158
42 World Health Organization (WHO). Suicide worldwide in 2019, global health estimates. Geneva: WHO; 2019. Accessed August 02, 2022 at: https://www.who.int/publications/i/item/9789240026643
43 Kachian ZR, Cohen-Zimerman S, Bega D. et al. Suicidal ideation and behaviour in Huntington’s disease: Systematic review and recommendations. J Affect Disord 2019; 250: 319-329
44 Paoli RA, Botturi A, Ciammola A. et al. Neuropsychiatric burden in Huntington’s disease. Brain Sci 2017; 7: 67
45 McGarry A, McDermott MP, Kieburtz K. et al. Risk factors for suicidality in Huntington disease An analysis of the 2CARE clinical trial. Neurology 2019; 92: e1643-e1651
46 Mulin E, Leone E, Dujardin K. et al. Diagnostic criteria for apathy in clinical practice. Int J Geriatr Psychiatry 2011; 26: 158-165
47 Gelderblom H, Wüstenberg T, McLean T. et al. Bupropion for the treatment of apathy in Huntington’s disease: A multicenter, randomised, double-blind, placebocontrolled, prospective crossover trial. PLoS ONE 2017; 12: e0173872
48 Karagas NE, Pessoa Rocha N, Stimming EF. Irritability in Huntington’s disease. J Huntingtons Dis 2020; 9: 107-113
49 Dale M, van Duijn E. Anxiety in Huntington’s disease. J Neuropsych Clin Neurosci 2015; 27: 262-271
50 Oosterloo M, Craufurd D, Nijsten H. et al. Obsessive-compulsive and perseverative behaviors in Huntington’s Disease. J Huntingtons Dis 2019; 8: 1-7
51 Anderson KE, Gehl CR, Marder KS. et al. Comorbidities of obsessive and compulsive symptoms in Huntington disease. Nerv Ment Dis 2010; 198: 334-338
52 Roman OC, Stovall J, Claassen DO. Perseveration and suicide in Huntington’s disease. J Huntingtons Dis 2018; 7: 185-187
53 Rasgon A, Lee WH, Leibu E. et al. Neural correlates of affective and non-affective cognition in obsessive compulsive disorder: A meta-analysis of functional imaging studies. Eur Psychiatry 2017; 46: 25-32
54 Hazari N, Narayanaswamy JC, Venkatasubramanian G. Neuroimaging findings in obsessive-compulsive disorder: A narrative review to elucidate neurobiological underpinnings. Indian J Psychiatry 2019; 61: S9-S29
55 Rocha NP, Mwnagi B, Gutierrez Candano CA. et al. The clinical picture of psychosis in manifest Huntington’s disease: A comprehensive analysis of the Enroll-HD Database. Front Neurol 2018; 9: 930
56 Ding J, Gadit AM. Psychosis with Huntington’s disease: role of antipsychotic medications. BMJ Case Rep 2014: 2013– 2015;
57 Majothi N, Lee HY, Nagarajan P. et al. Treatment of psychosis in Huntington’s disease with clozapine. Prog Neurol Psychiatry 2020; 24: 14-16
58 Wibawa P, Zombor R, Dragovic M. et al. Anosognosia is associated with greater caregiver burden and poorer executive function in Huntington disease. J Geriatric Psychiatry Neurol 2020; 33: 52-58
59 Sitek EJ, Thompson JC, Craufurd D. et al. Unawareness of deficits in Huntington’s disease. Jf Huntingtons Dis 2014; 3: 125-135
60 Duff K, Paulsen JS, Beglinger LJ. et al. „Frontal“ behaviors before the diagnosis of Huntington’s disease and their relationship to markers of disease progression: Evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci 2010; 22: 196-207
61 Herzog-Krzywoszanska R, Krzywoszanski L. Sleep disorders in Huntington’s disease. Front Psychiatry 2019; 10: 221
62 Voysey Z, Fazal SV, Lazar AS. et al. The sleep and circadian problems of Huntington’s disease: when, why and their importance. J Neurol 2021; 268: 2275-2283